All News

steroid prednisone lab

Corticosteroid Use Hikes CV Risks in Rheumatic Patients

Jack Cush, MD

UK Clinical Practice Research Datalink population study shows that patients with immune-mediated inflammatory diseases, such as RA, PMR, GCA and IBD, have an augmented risk of CV outcomes with glucocorticoid use; even lower doses had a near doubling of their underlying CVD risk.

Read Article
FINAL 2020 Podcast Graphic

RheumNow Podcast – Lights, Camera, Zoom (1.8.2021)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and favorite blogs from this past week on RheumNow.com.

Read Article
pill pillbox adherence

Adherence to Hydroxychloroquine Lowers Lupus Mortality

Jack Cush, MD

A lupus cohort study from British Columbia, Canada has shown that medication adherence with hydroxychloroquine (HCQ) is associated with a 71% to 83% lower mortality. 

Read Article
cardiac2.jpg (keep)

Rhapsody Study: IL-1 Inhibition in Recurrent Pericarditis

Jack Cush, MD

Recurrent pericarditis is a rare, probable autoinflammatory disorder mediated by interleukin-1 (IL-1); and is often refractory to glucocorticoids and colchicine.

Read Article
COVID USA Flag

COVID-19 as a Leading Cause of Death in the USA

Jack Cush, MD

The exponential rise in deaths from the coronavirus (COVID-19) in the last several months is put into perspective by JAMA Viewpoint article noting that current US death rates of > 3000 per day from COVID-19 is greater than that seen in one day on September 11, 2001 (9/11 attacks, claimed 2988 lives) or by a fictional catastrophe of 15 Airbus 320 jetliners (150 passengers each) crashing daily.

Read Article
lung%2Cbright.jpg

Rheumatoid arthritis and lung disease in the spotlight at #ACR20

Jeffrey Sparks, MD, MMSc

Rheumatoid arthritis (RA) has long been established to have pulmonary manifestations such as interstitial lung disease (ILD), and several research groups are pursuing this respiratory burden of RA at #ACR20. 

Read Article
Rhapsody Study: IL-1 Inhibition in Recurrent Pericarditis RHAPSODY was a phase 3 multicenter, double-blind, event-driven, randomized-withdrawal trial of rilonacept in 86 patients with recurrent pericarditis Read more: https://t.co/syibq4X7Ps https://t.co/gnxlpOGiHA

Links:

Dr. John Cush RheumNow ( View Tweet)
ENTRACTE trial studied the risk of major adverse CV events (MACE) in 3080 RA pts Rx with tocilizumab (TCZ) vs etanercept (ETN), and found no increased risk of MACE in TCZ patients compared to ETN (HR 1.05 (95% confidence interval 0.77–1.43). https://t.co/KpOEeVAAxx

Links:

Dr. John Cush RheumNow ( View Tweet)

#BestACR20Tweets RT @ATSCPAssembly : Dr. Dinesh Khanna ( @sclerodermaUM): In post-hoc analysis of focuSSed trial of tocilizumab vs. placebo, disease duration, male gender, elevated acute phase reactants, and anti-SCL-70 Ab have a larger beneficial effect on FVC in early SSc-ILD.

Dr. John Cush RheumNow ( View Tweet)

Lung Cancer Survival With Autoimmune Disease--a recent analysis suggests that patients with autoimmune disease do not have worse survival, even though they may have received less than the standard-of-care treatments. Learn more below. https://t.co/ItVhityI1B https://t.co/tyTKAtGY2O

Links:

Dr. John Cush RheumNow ( View Tweet)
Phase III RHAPSODY trial: open label rilonacept in 86 pts with active recurrent pericarditis (& elevated CRP). Rapid resolution was noted and during the drug withdrawal phase there were significantly fewer recurrences on rilonacept compared with placebo. https://t.co/oEGbsdKe8f

Links:

Dr. John Cush RheumNow ( View Tweet)

#UTSW Rheum Grand Rounds on Sarcoidosis w/ Dr. HSIA - Joints are involved in 15% of pts. Lung sking and ocular involvement predominate https://t.co/G4iWm4pLmO
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @drdavidliew :The 'triple M' irAEs (myositis/myocarditis/MG): one of the rheumatic irAEs where autoAb are freq pos Nice systematic review: any autoAb+ 61% tested MG+ 59% tested MSA+ in 27% tested (18/67, 11 had myositis alone) https://t.co/aQHapPbjw9
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @MeralElRamahiMD : A large observat study showed no difference in risk of major CV events in RA pts that were newly started on either MTX or HCQ. A greater stroke risk but lower risk of MI; hospitalized HF was seen in MTX initiators. #Abst1993 #ACR20

Dr. John Cush RheumNow ( View Tweet)

The Lungs: The Alpha and Omega of RA with Dr. Jonathan Kay #ACR20 https://t.co/zhCRaeKOfu https://t.co/zVwgzu9ULs

Links:

Dr. John Cush RheumNow ( View Tweet)
Citrulline Reactive B Cells Present in Lungs of Risk, Early RA: Richard Conway ( @RichardPAConway) discusses ACR abstract #1445 presented #ACR20 https://t.co/WjcBPay86P https://t.co/JnUVss0FDK

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @KDAO2011 : The FAST trial had 33% of pts with CVD and pts w/class III/IV CHF weren't allowed in this study; still cautious prescribing febuxostat to pts who have severe CVD until we have more data. https://t.co/eyl2kOjEEU https://t.co/qoQDgRifFg

Links:

Dr. John Cush RheumNow ( View Tweet)
Check out this quick video on lifestyle, clinical risk factors for RA-ILD with Dr. Sheila Reyes (@RHEUMarampa) #ACR20 https://t.co/7LQ7RCtiuj https://t.co/CjjtUauy2u

Links:

Dr. John Cush RheumNow ( View Tweet)
"Rheumatoid arthritis and lung disease in the spotlight at #ACR20" by Dr. Jeffrey Sparks ( @jeffsparks) https://t.co/0Dth0ko5TO https://t.co/e6HQOkXuY7

Links:

Dr. John Cush RheumNow ( View Tweet)
View our video on Abatacept in RA and ILD Patients with Dr Richard Conway ( @RichardPAConway) Dr. Richard Conway discusses abstract #0233 presented Friday at the #ACR20 virtual annual meeting. https://t.co/5zowsDetU1

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×